GenOway: Net Income Halved Despite a Rising 21% Margin
GenOway has emerged from a year of forced transformation. While its revenue declined by 5% in 2025 in a cautious economic environment, the Lyon-based biotech continued massive investments: doubling its sales force, launching an aggressive marketing campaign, and acquiring new assets in data science and artificial intelligence. These expenses have dented the net result, which fell to 0.9 million euros. However, EBITDA remains high at 4.4 million euros, confirming a 21% margin. This tension between a decline in activity and the maintenance of profitability reveals a two-step strategy: accepting compressed results today to reap benefits tomorrow. The central question now is: will the committed investments bear the promised fruits?
Revenue and Profitability Analysis
GenOway recorded consolidated revenue of 21.0 million euros in 2025, down by 1.1 million euros from 2024 (22.1 million euros). This 5% contraction occurred in a generally cautious economic environment, according to the company. EBITDA stands at 4.4 million euros, slightly below the 4.4 million euros of 2024, while the EBITDA margin has progressed to 20.8% (rounded to 21% in company communications), compared to 20.1% the previous year. Operating income fell to 1.534 million euros from 1.812 million euros, and net income declined to 0.928 million euros from 1.831 million euros in 2024. This weakening at the bottom line reflects the impact of massive investments made during the fiscal year, including a complete overhaul of the commercial organization with a doubling of the sales force and a new marketing plan described as aggressive by management.
Cost Savings and Productivity Improvements
Alongside the increase in commercial expenses and continuing intense R&D efforts, GenOway implemented several cost-saving and productivity improvement plans at the beginning of 2025. These actions generated production savings of about 0.8 million euros in 2025, in line with the announced target. More significantly, management anticipates an additional 1.4 million euros in savings in 2026, totaling 2.2 million euros in reduced variable expenses over the two fiscal years—a reduction of nearly 25%. Despite this operational efficiency gain, the company remains committed to heavy investments for the future: a structural investment of 7.3 million euros was made in 2025, fully financed by a 15-year loan, for acquiring a new building dedicated to expanding production capacities and new service offerings. These efforts to rationalize variable costs demonstrate a balanced strategy aimed at absorbing growth expenses without permanently degrading the EBITDA margin.
Anticipated Growth and Strategic Goals
GenOway anticipates a positive year in 2026 with double-digit growth, based on three pillars: first, the full deployment of the new commercial structure established in 2025 and its new marketing efforts; second, the launch of two new catalog model lines—one in inflammation, the other in safety (toxicity evaluation)—currently in the validation phase; and crucially, the ramp-up of international development in Asia. GenOway expects its joint venture, genOway Shanghai, to double its revenue in 2026 compared to 2025, with a target between 5 and 10 million euros in revenue by 2028. In Japan, the new subsidiary is expected to generate its first sales by the end of the first half of 2026. Several other distributors will be opened in Asia and some Western markets in 2026. In the longer term, GenOway confirms the initial goals of its strategic plan ROUTE50+: to reach a consolidated revenue of 50 million euros by 2028, accompanied by an EBITDA margin above 15%. Management plans to update these targets during 2026 to integrate additional revenues from the acquisition of omics and data science/AI assets completed in December 2025. GenOway has strengthened its financial structure with equity capital at 25.0 million euros and available cash of 7.1 million euros at the end of 2025, after a private placement of 7 million euros in December. Financial debts amount to 13.8 million euros.
